Type
|
Public |
---|---|
Traded as | NYSE: SYK S&P 500 Component |
Industry | Medical technology |
Founded | 1946 |
Founder | Homer Stryker |
Headquarters | Kalamazoo, Michigan, U.S.A. |
Key people
|
John W. Brown – Chairman emeritus Kevin A. Lobo – President & Chief Executive Officer |
Products | Medical devices orthopaedic implants surgical equipment neurovascular products patient handling and emergency medical equipment |
Revenue | $9.021 billion USD (2013) |
Operating income
|
$1.741 billion USD (2012) |
Number of employees
|
Approx. 33,000 (05/01/17) |
Website | www.stryker.com |
Stryker Corporation (NYSE: SYK) is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
In the United States, most of Stryker's products are marketed directly to doctors, hospitals and other healthcare facilities. Internationally, Stryker products are sold in over 100 countries through company-owned sales subsidiaries and branches as well as third-party dealers and distributors.
Stryker segregates their reporting into three reportable business segments: Orthopedics, Medical and Surgical (MedSurg), and Neurotechnology and Spine.
Orthopedics products consist primarily of implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg products include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices as well as other medical device products used in a variety of medical specialties. Stryker Neurotechnology and Spine products include a portfolio of products including both neurosurgical and neurovascular devices. Their neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Stryker also develops, manufactures and markets spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.
The Orthopedic Frame Company, the precursor of Stryker Corporation, was formed on February 20, 1946, by Dr. Homer Stryker, a Kalamazoo, Michigan, orthopedist. Stryker developed the Turning Frame, a mobile hospital bed that allowed for repositioning of injured patients while providing necessary body immobility; the cast cutter, a cast cutting apparatus that removed cast material without damaging underlying tissues; and the walking heel, among others. In 1964, the company name was officially changed to Stryker Corporation.
In 1979, Stryker made an initial public offering of stock and later acquired Osteonics Corporation, entering the replacement hip, knee, and other orthopedic implants market (Stryker). In 1999 annual sales reached $2.1 billion, and in 2000 Stryker was included in the S&P 500 and the Forbes Platinum 400 for the first time. In 2002 sales reached $3.0 billion and Stryker was listed in the Fortune 500 for the first time.
In 2003, Stephen P. MacMillan joined Stryker as President and CEO. In 2005, annual sales reached $4.9 billion and John W. Brown transitioned to the single role of Chairman of the Board, a role he retired from in 2010, while Steve MacMillan became President & CEO. By 2007, Stryker sold its Physiotherapy Associates division to private equity firm Water Street Healthcare Partners for $150 million. In February 2012, Mr. MacMillan resigned and Curt R. Hartman was named Interim Chief Executive Officer and Vice President and Chief Financial Officer. Mr. William U. Parfet was named Non-Executive Chairman of the Board. On October 1, 2012, Mr. Kevin A. Lobo was appointed as President and Chief Executive Officer.
At the end of 2012, Stryker had approximately 22,000 global employees and annual sales of $8.7 billion. 35% of those sales were outside the U.S.
In a 2012 global market overview of top medical technology firms, Stryker was ranked number 10 with total portfolio sales in excess of $8.6 billion. Moreover, the firm maintains 35% worldwide reconstructive market share; 50% worldwide MedSurg market share; 15% worldwide Neurotechnology and Spine market share.
The company was recognized by Hermann Simon as a role model for other small to medium-sized business in his book Hidden Champions.
Brown served as President, CEO and finally Chairman of the Board across a 32-year career with Stryker. One report attributes Stryker's rise from a maker of hospital beds to a world-class medical technology company to Brown. As of 2013, Brown's retained investment in Stryker placed him on the Forbes 400 list with a net worth of US$1,500,000,000.
As of 2014, members of the board of directors of Stryker Corporation are:
In 1998, Stryker purchased Howmedica, the orthopaedic division of Pfizer, for $1.65 billion. Howmedica became Stryker Orthopaedics. In August 2000, Stryker acquired, with stock, Guided Technologies, Inc., a developer and manufacturer of optical localizers purposed for use in healthcare and industrial.
In August 2004, Stryker acquired, for $120 million, SpineCore Inc., a company involved in the development of artificial spinal disks. About two years preceding this date, in June 2002, the firm acquired the Spinal Implant Business of Surgical Dynamics Inc. for $135 million.
In March 2006, Stryker absorbed the Haifa, Israel-based Sightline Technologies Ltd. into its operations. Sightline, a manufacturer of gastrointestinal endoscopy apparatuses, propelled Stryker into the flexible endoscopy market. In February of the same year, the firm acquired eTrauma.com Corp., a privately held entity involved in the development of software for Picture archiving and communication system (PACS); the company was incorporated into Stryker Endoscopy Business. December 2005 marked the company's acquisition of PlasmaSol Corp. for $17.5 million. PlasmaSol produces technologies allowing sterilization of various MedSurg equipments.
In 2009, Stryker acquired Ascent Healthcare Solutions, Inc. the market leader in the reprocessing and remanufacturing of medical devices in the U.S.
In Jan 2011, Stryker acquired the Neurovascular Division of Boston Scientific, which includes products used for the minimally invasive treatment of hemorrhagic and ischemic stroke. In June 2011, Stryker purchased Malvern, Pennsylvania-based Orthovita, a biomaterials company specializing in bone augmentation and substitution technologies. The Orthovita business now makes up the Stryker Orthobiologics division, which specializes in biomaterials for all Stryker divisions. In July 2011, Stryker completed the acquisition of privately held Memometal Technologies S.A.. France based Memometal develops, manufactures and markets products for extremity indications based on its proprietary methods for preparing and manufacturing a shape memory metal alloy. In August 2011, Stryker signed a definitive agreement to acquire privately held Concentric Medical, Inc. in an all-cash transaction for $135 million. Concentric's products include devices for the removal of thrombus in patients experiencing acute ischemic stroke along with a broad range of AIS access products.
In November 2012, Stryker acquired the Tel Aviv, Israel-based Surpass Medical Ltd., a company developing a flow diversion stent technology to treat brain aneurysms using a mesh design and delivery system, for $135 million.
In March 2013, Stryker acquired Trauson Holdings Company Limited. Trauson is a trauma manufacturer in China and a major competitor in the spine segment. In December 2013, Stryker acquired MAKO Surgical Corporation. MAKO is a company in South Florida that manufactures and markets surgical robotic arm assistance platforms, most notably the RIO (Robotic Arm Interactive Orthopedic System) as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. Stryker also acquired Patient Safety Technologies, Inc. The company offers Safety-Sponge System, an integrated counting and documentation system that prevents surgical sponges and towels from being unintentionally left in patients after surgical procedures.
In March 2014, Stryker acquired Pivot Medical, Inc. Pivot is a privately held business selling innovative products for hip arthroscopy with operating facilities in Sunnyvale, CA. In April 2014 Stryker acquires Berchtold Holding AG (Berchtold), a provider of customer-centric healthcare equipment for over 90 years. Berchtold's product portfolio includes surgical tables, equipment booms, and surgical lighting systems geared towards maximizing efficiency and safety in operating rooms and ICUs. On July 1, 2014, Stryker Corp. announced that it had agreed to buy the assets of Small Bone Innovations Inc., a Morrisville, Pa.-based company that specializes in products that help surgeons treat and replace small bones and joints for $358 million. The company also acquired Patient Safety Technologies for $120 million.
In September 2015, Stryker acquired Turkish company Muka Metal A.S. which is manufacturing hospital beds and patient furniture in Kayseri.
In February 2016, the company announced it would acquire Sage Products for $2.8 billion. Later in the same month the company announced the acquisition of Physio-Control International from Bain Capital Private Equity for $1.28 billion.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Stryker Corporation
(Est 1946 as The Orthopedic Frame Company)
Osteonics Corporation
Howmedica
(Acq 1998)
Guided Technologies, Inc.
(Sold 2007)SpineCore Inc.
Water Street Healthcare Partners
(Physiotherapy Associates div; Sold 2007)
Surgical Dynamics Inc.
(Spinal Implant div; Acq 2002)
SpineCore Inc.
(Acq 2004)
PlasmaSol Corp.
(Acq 2005)
Sightline Technologies Ltd
(Acq 2006)
eTrauma.com Corp.
(Acq 2006; Incorporated into Stryker Endoscopy div)
Water Street Healthcare Partners
(Physiotherapy Associates div; Sold 2007)
Ascent Healthcare Solutions, Inc.
(Acq 2009)
Boston Scientific
(Neurovascular div; Acq 2011)
Orthovita
(Acq 2011; incorporated into Stryker Orthobiologics div)
Memometal Technologies S.A.
(Acq 2011)
Concentric Medical, Inc.
(Acq 2011)
Surpass Medical Ltd
(Acq 2012)
Trauson Holdings Company Limited
(Acq 2013)
MAKO Surgical Corporation
(Acq 2013)
Patient Safety Technologies
(Acq 2013)
Pivot Medical, Inc.
(Acq 2014)
Berchtold Holding AG
(Acq 2014)
Small Bone Innovations Inc.
(Acq 2014)
Sage Products
(Acq 2016)
Physio-Control International
(Acq 2016)
Stanmore Implants Worldwide Ltd
(Acq 2016)
Stryker maintains relationships with, but not limited to, the following professional and trade organizations:
Additionally, the following athletes publicly endorse Stryker Orthopaedics products:
Stryker is also a major sponsor of a FIRST Robotics team, #2767 "Stryke Force", out of Kalamazoo. Originally known as "FLEET", the name was changed to reflect the generous sponsorship from Stryker.
On Jan 27, 2000, Stryker Corporation restated its operating results for the year ended December 31, 1998, to reduce acquisition-related charges by $30.9 million.
Since early 2007, the company has received three warning letters from the Food & Drug Administration citing issues in compliancy. The first of these, a seven-page correspondence, named various issues at an Irish manufacturing facility, such as untimely fix of failures and procedural noncompliance in the testing of failed or otherwise problem-prone devices. The second, sent November 2007, cites issues at the firm's Mahwah, New Jersey, facility, including poor fixation of hip implant components, in some instances requiring mitigation by revision surgeries; exceeded microbial level violations in the cleaning and final packaging areas of the sterile implants; and failure to institute measures in prevention of recurrence of these and other problems. The final warning letter, sent April 2008, cites issues at the firm's Hopkinton, MA biotechnology facility. Again, issues relate to quality and noncompliance including falsification of documents relevant to the selling of products to hospitals which are to be sold under a limited, government-mandated basis. Stryker maintains that employees involved in the falsification of documents have since been terminated.
In the Fall of 2007, Stryker, along with the related companies: Biomet, Zimmer Holdings, DePuy Orthopaedics and Smith & Nephew, were involved in civil ligation with the U.S. Department of Health and Human Services, Office of Inspector General. This litigation called for a net payout of $311 million as the governmental department maintains the aforementioned companies engaged in unlawful kickbacks to physicians who urged hospitals to purchase their respective products. Stryker, however, having cooperated early in the investigation, was not fined.
As of February 2008, a dispute exists between Stryker Corp. and the U.S. Department of Justice concerning a subpoena linking the company to aforementioned misconduct in sale of products. Since governmental filing of the injunction, Stryker notes that it has produced in excess of 300,000 pages of documentation in compliance with the mandate. U.S. Government counters, however, that the documentation was not proper in scope and format. Law officials expect the investigation to continue for several months.
Stryker recalled several models of medical vacuums sold under the Neptune Waste Management System brand in June and September 2012. The devices, some of which had not been cleared by the Food and Drug Administration, caused a fatal accident when the vacuum was mistakenly used to suction a passive drainage tube.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-10-26 | Future report Set alerts | |
Q2 2022 | 2022-07-26 | 2.25 | 2.25 |
Q1 2022 | 2022-04-28 | 1.97 | 1.97 |
Q4 2021 | 2022-01-27 | 2.71 | 2.71 |
Q3 2021 | 2021-10-28 | 2.20 | 2.20 |
Q2 2021 | 2021-07-27 | 2.25 | 2.25 |
Q1 2021 | 2021-04-27 | 1.93 | 1.93 |
Q4 2020 | 2021-01-27 | 2.81 | 2.81 |
Q3 2020 | 2020-10-29 | 2.14 | 2.14 |
Q2 2020 | 2020-07-30 | 0.64 | 0.64 |
2016-06-08 | Initiated Coverage | Guggenheim | Buy | $134.00 |
2016-04-27 | Boost Price Target | Argus | Buy | $120.00 to $130.00 |
2016-04-27 | Upgrade | Sterne Agee CRT | Neutral to Buy | $130.00 |
2016-04-27 | Reiterated Rating | Brean Capital | Buy | $121.00 |
2016-04-26 | Boost Price Target | RBC Capital | Outperform | $108.00 to $120.00 |
2016-04-26 | Boost Price Target | Royal Bank Of Canada | Outperform | $108.00 to $120.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray | Buy | $110.00 to $120.00 |
2016-04-21 | Reiterated Rating | Canaccord Genuity | Buy | |
2016-04-21 | Reiterated Rating | Leerink Swann | Buy | $111.00 to $125.00 |
2016-04-21 | Reiterated Rating | Brean Capital | Buy | |
2016-04-21 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-04-21 | Reiterated Rating | Piper Jaffray Cos. | Buy | $110.00 to $120.00 |
2016-04-13 | Downgrade | Robert W. Baird | Outperform to Neutral | $111.00 to $116.00 |
2016-04-11 | Initiated Coverage | Barclays | Underweight | $107.00 |
2016-04-11 | Initiated Coverage | Barclays PLC | Underweight | $107.00 |
2016-04-08 | Boost Price Target | Goldman Sachs | $107.00 to $119.00 | |
2016-04-08 | Boost Price Target | Goldman Sachs Group Inc. | $107.00 to $119.00 | |
2016-03-28 | Boost Price Target | SunTrust | Reduce to Reduce | $64.00 to $74.00 |
2016-03-28 | Boost Price Target | Stifel Nicolaus | Buy | $92.00 to $105.00 |
2016-03-28 | Boost Price Target | Oppenheimer | Market Perform | $73.00 to $83.00 |
2016-03-28 | Boost Price Target | Leerink Swann | Outperform | $87.00 to $92.00 |
2016-03-28 | Boost Price Target | Jefferies Group | Hold | $74.00 to $83.00 |
2016-03-28 | Boost Price Target | Canaccord Genuity | Buy | $76.00 to $82.00 |
2016-03-28 | Boost Price Target | BMO Capital Markets | Market Perform | $77.00 to $86.00 |
2016-03-28 | Boost Price Target | SunTrust Banks Inc. | Reduce to Reduce | $64.00 to $74.00 |
2016-03-28 | Boost Price Target | Oppenheimer Holdings Inc. | Market Perform | $73.00 to $83.00 |
2016-03-17 | Initiated Coverage | Nomura | Neutral | $115.00 |
2016-03-17 | Initiated Coverage | Nomura Holdings Inc. | Neutral | $115.00 |
2016-02-20 | Reiterated Rating | Piper Jaffray | Overweight | $110.00 |
2016-02-17 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-02-16 | Reiterated Rating | Canaccord Genuity | Buy | $113.00 |
2016-02-02 | Boost Price Target | Deutsche Bank | Buy | $107.00 to $113.00 |
2016-02-02 | Boost Price Target | Deutsche Bank AG | Buy | $107.00 to $113.00 |
2016-01-28 | Reiterated Rating | Oppenheimer | Market Perform | $104.00 |
2016-01-28 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-01-27 | Boost Price Target | Deutsche Bank | Buy | $107.00 to $113.00 |
2016-01-27 | Reiterated Rating | Canaccord Genuity | Buy | $112.00 |
2016-01-27 | Upgrade | Brean Capital | Hold to Buy | $115.00 |
2016-01-19 | Downgrade | Needham & Company LLC | Hold | |
2016-01-13 | Reiterated Rating | Brean Capital | Hold | |
2016-01-07 | Downgrade | Northland Securities | Outperform to Market Perform | |
2015-12-14 | Downgrade | BMO Capital Markets | Market Perform to Underperform | $105.00 to $88.00 |
2015-11-13 | Downgrade | Goldman Sachs | Buy to Neutral | $111.00 |
2015-11-12 | Initiated Coverage | Citigroup Inc. | Sell | $88.00 |
2015-11-04 | Initiated Coverage | Sterne Agee CRT | Neutral | |
2015-10-23 | Reiterated Rating | Brean Capital | Hold | |
2015-10-23 | Reiterated Rating | Deutsche Bank | Buy | |
2015-10-23 | Boost Price Target | Robert W. Baird | Outperform | $108.00 to $111.00 |
2015-10-23 | Lower Price Target | Leerink Swann | Outperform | $110.00 to $109.00 |
2015-10-23 | Reiterated Rating | Canaccord Genuity | Buy | $112.00 |
2015-10-23 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-09-28 | Downgrade | Needham & Company LLC | Buy to Hold | |
2015-08-27 | Boost Price Target | Goldman Sachs | $114.00 to $117.00 | |
2015-08-27 | Reiterated Rating | Piper Jaffray | Overweight | $110.00 |
2015-08-12 | Boost Price Target | Stifel Nicolaus | Buy | $115.00 to $123.00 |
2015-08-10 | Reiterated Rating | Credit Suisse | Buy | $100.00 to $110.00 |
2015-08-10 | Reiterated Rating | Credit Suisse Group AG | Buy | $100.00 to $110.00 |
2015-08-05 | Boost Price Target | Argus | Buy | $110.00 to $120.00 |
2015-07-29 | Reiterated Rating | Deutsche Bank | Buy | $106.00 |
2015-07-27 | Reiterated Rating | Leerink Swann | Outperform | $105.00 to $110.00 |
2015-07-25 | Reiterated Rating | Needham & Company LLC | Buy | $107.00 to $112.00 |
2015-07-24 | Boost Price Target | Canaccord Genuity | Buy | $108.00 to $110.00 |
2015-07-24 | Boost Price Target | RBC Capital | Outperform | $100.00 to $108.00 |
2015-07-22 | Reiterated Rating | Brean Capital | Hold | |
2015-06-17 | Reiterated Rating | Canaccord Genuity | Buy | $108.00 |
2015-05-14 | Initiated Coverage | Northland Securities | Outperform | $109.00 |
2015-04-23 | Reiterated Rating | Argus | Buy | $102.00 to $110.00 |
2015-04-22 | Boost Price Target | Deutsche Bank | Buy | $100.00 to $106.00 |
2015-04-22 | Boost Price Target | Canaccord Genuity | Buy | $102.00 to $108.00 |
2015-04-22 | Boost Price Target | Needham & Company LLC | Buy | $104.00 to $107.00 |
2015-04-02 | Downgrade | Barclays | Equal Weight to Underweight | $88.00 to $92.00 |
2015-03-27 | Set Price Target | Morgan Stanley | Buy | $105.00 |
2015-03-03 | Set Price Target | Canaccord Genuity | Buy | $102.00 |
2015-02-15 | Reiterated Rating | Canaccord Genuity | Buy | $102.00 |
2015-01-28 | Reiterated Rating | William Blair | Buy | |
2015-01-28 | Boost Price Target | Jefferies Group | Hold | $85.00 to $94.00 |
2015-01-28 | Reiterated Rating | Brean Capital | Hold | |
2015-01-28 | Boost Price Target | Stifel Nicolaus | Buy | $92.00 to $105.00 |
2015-01-27 | Boost Price Target | Credit Suisse | Outperform | $90.00 to $100.00 |
2015-01-26 | Set Price Target | Canaccord Genuity | Buy | $100.00 to $102.00 |
2015-01-15 | Reiterated Rating | Canaccord Genuity | Buy | |
2015-01-15 | Reiterated Rating | Brean Capital | Hold | |
2015-01-14 | Boost Price Target | Needham & Company LLC | Buy | $101.00 to $105.00 |
2015-01-05 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $90.00 to $94.00 |
2014-12-05 | Boost Price Target | Leerink Swann | Outperform | $92.00 to $106.00 |
2014-12-02 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | |
2014-12-01 | Boost Price Target | Needham & Company LLC | Buy | $93.00 to $101.00 |
2014-11-24 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $85.00 to $90.00 |
2014-10-17 | Reiterated Rating | Deutsche Bank | Buy | $92.00 |
2014-10-17 | Reiterated Rating | Canaccord Genuity | Buy | $88.00 to $84.00 |
2014-08-12 | Upgrade | Needham & Company LLC | Hold to Buy | |
2014-07-21 | Reiterated Rating | Citigroup Inc. | Neutral | $85.00 to $90.00 |
2014-07-18 | Reiterated Rating | Cantor Fitzgerald | Hold | |
2014-07-18 | Boost Price Target | Oppenheimer | Market Perform | $83.00 to $85.00 |
2014-07-18 | Boost Price Target | BMO Capital Markets | $86.00 to $88.00 | |
2014-07-18 | Boost Price Target | Jefferies Group | Hold | $83.00 to $85.00 |
2014-07-18 | Boost Price Target | Canaccord Genuity | Buy | $85.00 to $88.00 |
2014-07-18 | Boost Price Target | Barclays | Equal Weight | $79.00 to $85.00 |
2014-07-01 | Boost Price Target | Cantor Fitzgerald | $78.00 to $84.00 | |
2014-06-11 | Upgrade | Argus | Hold to Buy | $102.00 |
2014-06-04 | Boost Price Target | Sanford C. Bernstein | $84.00 to $89.00 | |
2014-04-24 | Lower Price Target | JPMorgan Chase & Co. | $83.00 to $82.00 | |
2014-04-24 | Boost Price Target | Canaccord Genuity | Buy | $82.00 to $85.00 |
2014-04-14 | Upgrade | SunTrust | Reduce to Neutral | $74.00 to $84.00 |
2014-03-17 | Boost Price Target | Cowen and Company | $86.00 to $91.00 | |
2014-01-23 | Boost Price Target | Canaccord Genuity | Buy | $76.00 to $82.00 |
2014-01-13 | Boost Price Target | Credit Suisse | $77.00 to $84.00 | |
2014-01-09 | Boost Price Target | Barclays | Equal Weight | $76.00 to $79.00 |
2013-12-18 | Boost Price Target | JPMorgan Chase & Co. | $78.00 to $80.00 | |
2013-11-25 | Upgrade | Sanford C. Bernstein | Market Perform to Outperform | $75.00 to $84.00 |
2013-10-22 | Boost Price Target | Piper Jaffray | Neutral | $74.00 to $82.00 |
2013-10-18 | Boost Price Target | Jefferies Group | Hold | $69.00 to $74.00 |
2013-10-18 | Boost Price Target | Canaccord Genuity | Buy | $72.00 to $76.00 |
2013-09-25 | Reiterated Rating | Wells Fargo & Co. | Outperform | |
2013-09-25 | Reiterated Rating | Wells Fargo | Outperform | |
2013-09-24 | Boost Price Target | RBC Capital | Outperform | $74.00 to $81.00 |
2012-12-18 | Downgrade | Standpoint Research | Buy to Hold |
2016-06-08 | Initiated Coverage | Guggenheim | Buy | $134.00 |
2016-04-27 | Boost Price Target | Argus | Buy | $120.00 to $130.00 |
2016-04-27 | Upgrade | Sterne Agee CRT | Neutral to Buy | $130.00 |
2016-04-27 | Reiterated Rating | Brean Capital | Buy | $121.00 |
2016-04-26 | Boost Price Target | RBC Capital | Outperform | $108.00 to $120.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SYK 976 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 29.80M |
BlackRock Inc. | 23.66M |
PRICE T ROWE ASSOCIATES INC /MD/ | 20.13M |
GREENLEAF TRUST | 19.81M |
WELLINGTON MANAGEMENT CO LLP | 17.65M |
STATE STREET CORP | 14.05M |
Capital Research Global Investors | 12.63M |
BlackRock Institutional Trust Company, N.A. | 8.72M |
BlackRock Fund Advisors | 6.32M |
GEODE CAPITAL MANAGEMENT, LLC | 5.70M |
Fundsmith LLP | 5.63M |
MORGAN STANLEY | 4.91M |
FRANKLIN RESOURCES INC | 4.85M |
Fisher Asset Management, LLC | 3.58M |
NORTHERN TRUST CORP | 3.51M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
COX HOWARD E JR | 0.14% (525452) | MXC / SYK / |
PARFET WILLIAM U | 0.07% (281291) | MON / SYK / TCO / |
STRYKER RONDA E | 0.06% (209877) | SYK / |
Hall Curtis E V.P. and General Counsel | 0.05% (183077) | SYK / |
Scannell Timothy J Group President | 0.03% (130501) | PODD / SYK / |
Carpenter Lonny J Group President | 0.03% (101675) | SYK / |
Lobo Kevin President and CEO | 0.01% (49443) | PH / SYK / |
McKinney Tony M V.P., Chief Accounting Officer | 0.01% (36753) | SYK / |
Subrahmanian Ramesh Group President | 0.01% (20448) | SYK / |
Floyd David Group President, Orthopaedics | 0.01% (20214) | NNBR / SYK / |
Doliveux Roch | 0.01% (19560) | SYK / |